Dawaa Reference

chronic

Stammering (Stuttering)

Treatment options, dosing, cautions and Egyptian brands from the shipped Dawaa Reference card.

Evidence status

Checked against the sources named below

Sources4 sources

ICPC-3 (WONCA International Classification of Primary Care, 3rd edition) class NS11.00 - condition scope only, no dose · No dose - referral pathway, no medicine given in primary care · Stuttering (Stammering) - StatPearls - NCBI Bookshelf - https://www.ncbi.nlm.nih.gov/books/NBK603738/ · Stammering (Stuttering) - disease-level clinical article (stammering-full.txt)

Verified against3 documents
  • No dose - referral pathway, no medicine given in primary care
  • Stammering (Stuttering) - disease-level clinical article (stammering-clinical.txt)
  • Stammering (Stuttering) - disease-level clinical article (stammering-full.txt)

Verified date2026-08

Presentation reference

Is it this?

Reference only, to read alongside your own examination.

Symptoms — what the patient reports (7)

  • Adverse emotional reactions related to the stutter and its secondary behaviors are part of the picture [stuttering]
  • Neurogenic stuttering follows an acute neurological event, appearing anywhere from almost immediately to several months later, but always with sudden onset [stuttering]
  • Tremor, headache, poor coordination, or one-sided weakness alongside stuttering point to a neurological cause [headache · one-sided weakness · stuttering · tremor]
  • The stutter itself bothers the patient, but does not typically trigger anxiety in the neurogenic form [stuttering]
  • Psychogenic stuttering tends to ease once the patient puts their emotions into words [stuttering]
  • In psychogenic stuttering, unusual body movements and anxiety features show up independent of the speech itself [anxiety · stuttering]
  • Medication history matters, since drugs affecting central nervous system neurotransmitters can point to drug-induced stuttering [stuttering]

Signs — what you find (11)

  • Fluency improves on repeated reading of the same passage - the adaptation effect
  • Stuttering reduces or disappears when singing or speaking in unison with another person - the choral effect [stuttering]
  • Longer, more complex sentences bring on more stuttering [stuttering]
  • Secondary behaviors such as grimacing, jaw jerks, or head movements can develop to offset the stutter [stuttering]
  • Neurogenic stuttering favors repeated sounds and syllables, with blocks that can occur anywhere in speech rather than just at the start [stuttering]
  • The adaptation effect is typically absent in neurogenic stuttering, and the pattern stays consistent across conversation, reading, and repetition tasks
  • Neurogenic stuttering can coexist with dysarthria or other speech disorders [slurred speech · stuttering]
  • Secondary behaviors like blinking or facial grimaces are uncommon in neurogenic stuttering, and when present are not tied to active stuttering episodes [stuttering]
  • Psychogenic stuttering typically has an abrupt onset with disfluencies that can appear anywhere in speech and an unusual voice quality [stuttering]
  • Psychogenic stuttering shows no features of a neurological problem and no other communication disorder such as dysarthria [stuttering]
  • Psychogenic stuttering can persist even in situations that would normally improve fluency, and may involve broken-English speech patterns [stuttering]

Tests (7)

  • A comprehensive evaluation covers 6 core areas, using tools like case-history forms, interviews, and observation of speech and fluency across tasks
  • Screening should cover language and speech development, temperament, and hearing along with other relevant abilities
  • Standardized instruments such as the Stuttering Severity Instrument and the Speech Situation Checklist rate fluency and emotional reaction
  • Impact on daily life can be measured with tools such as OASES or the WASSP self-rating profile
  • A full neurological exam is required to rule out a neurogenic cause
  • Motor speech assessment helps pick up a coexisting motor speech disorder often seen with neurogenic stuttering
  • CT or MRI brain imaging may reveal a lesion behind neurogenic stuttering

If not this — what else fits (1)

  • Developmental stuttering must be told apart from the disfluencies that are a normal part of childhood speech

SourceStatPearls "Stuttering (Stammering)" - disease-level clinical article

Presentation findings are traced to the source above.

1

SPEECH AND LANGUAGE THERAPY REFERRAL (RECOGNITION & REFERRAL)

1st line
Adult dose and duration

A fluency disorder, usually developmental and beginning in childhood. The definitive management is speech and behavioural therapy, started early - the article's reasoning is that starting young exploits the plasticity of the nervous system, and that several kinds of speech and behavioural therapy are used, each chosen against the individual's needs, therapeutic objectives and response. The named programmes include the Lidcombe programme, which trains parents to praise fluent speech and to respond appropriately when speech is stuttered, alongside RESTART-DCM, Palin PCI, Westmead, Camperdown and the Van Riper method. There is no drug for it, and the article says so outright: medication has not been shown to work in developmental or persistent stuttering. Refer to a speech-language pathologist. - Refer, with advice

Paediatric dose

Children follow the same pathway: recognise and refer. No primary-care medicine is implied.

Dose source

No dose - referral pathway, no medicine given in primary care

Why

A fluency disorder, usually developmental and beginning in childhood. The definitive management is speech and behavioural therapy, started early - the article's reasoning is that starting young exploits the plasticity of the nervous system, and that several kinds of speech and behavioural therapy are used, each chosen against the individual's needs, therapeutic objectives and response. The named programmes include the Lidcombe programme, which trains parents to praise fluent speech and to respond appropriately when speech is stuttered, alongside RESTART-DCM, Palin PCI, Westmead, Camperdown and the Van Riper method. There is no drug for it, and the article says so outright: medication has not been shown to work in developmental or persistent stuttering. Refer to a speech-language pathologist.

Cautions
  • RED FLAG - Psychiatric referral or counselling is called for regardless of the underlying cause, to prevent adverse mental health outcomes - alongside speech and language therapy referral.
  • RED FLAG - Refer any child with stutter-like disfluencies to a speech-language pathologist, whether the parents report them or you observe them. Referral is more urgent if the disfluency has persisted for a year or more, or if parents report worsening severity or increasing frequency.
  • No drug row is listed here because the article rules one out for THIS condition, not because nothing was looked for. It does name drugs, but for a different entity, and the distinction is the whole point: it sets neurogenic stuttering apart from developmental stuttering and allows medication only for the former. The drugs it lists there are the antipsychotics - haloperidol commonest, then chlorpromazine, trifluoperazine and thioridazine, with risperidone and olanzapine among the newer ones - and the anticonvulsants carbamazepine, sodium valproate and levetiracetam. It adds that they are not usually the first thing reached for, because adverse effects are so frequent, and that speech therapy is the mainstay. (Stuttering (Stammering) - StatPearls - NCBI Bookshelf, NBK603738) Neurogenic stuttering follows a stroke, head injury or other brain lesion, which is a different diagnosis from this one.
  • If the stammer started after a drug was started, the answer is the drug, not another drug. The article's treatment for drug-induced stuttering is to stop the agent responsible, or else to change its dose or how often it is given. (Stuttering (Stammering) - StatPearls - NCBI Bookshelf, NBK603738)
  • RED FLAG - Sudden adult-onset stammering can signal a neurological event such as a stroke rather than developmental stuttering.

Prices are indicative (dataset snapshot 2026-06); verify with the pharmacy.